|
| Study | Total number of patients | Female (%) | Type of spondyloarthropathy (if any) |
|
|
Wakefield et al. 1984 [9] | 40 | 21/40 (52.5%) | HLA-B27-negative AU |
| 41 | 9/41 (22%) | HLA-B27-associated AU* |
| | 8/18 (44%) | Idiopathic HLA-B27-associated AU |
| | 0/7 (0%) | AU + Reiters syndrome |
| | 0/11 (0%) | AU + ankylosing spondylitis |
| | 1/4 (25%) | AU + seronegative arthritis |
| | 0/1 (0%) | AU + IBD |
|
|
Rothova et al. 1992 [7] | 73 | 21/73 (29%) | HLA-B27-associated AU |
|
|
Linssen and Meenken 1995 [11] | 35 | 18/35 (51%) | HLA-B27-negative AU |
| 119 | 43/119 (36%) | HLA-B27-associated AU* |
| | 24/40 (60%) | Idiopathic HLA-B27-associated AU* |
| | 16/44 (36%) | AU + ankylosing spondylitis* |
| | 8/35 (23%) | AU + AS-related spondyloarthropathy* |
|
|
Tay-Kearney et al. 1996 [12] | 148 | 59†/148 (40%) | HLA-B27-associated AU* |
| | 14/37 (38%) | AU + ankylosing spondylitis |
| | 4/22 (18%) | AU + Reiters syndrome |
| | 5/9 (55.5%) | AU + incomplete Reiters syndrome |
| | 1/5 (20%) | AU + psoriatic arthritis and/or spondylitis |
| | 2/3 (67%) | AU + IBD and/or spondylitis |
| | 4/7 (57%) | AU + undifferentiated spondyloarthropathy |
|
|
Lyons and Rosenbaum 1997 [19] | 17 | 14/17 (82%) | Uveitis + IBD |
| 89‡ | 29/89 (33%) | Uveitis + spondyloarthropathy |
|
|
Power et al. 1998 [3] | 191 | 86/191 (45%) | HLA-B27-associated AU |
| | 52/97 (54%) | AU without systemic disease |
| | 17/51 (33%) | AU + ankylosing spondylitis |
| | 5/26 (19%) | AU + Reiters syndrome |
| | 4/5 (80%) | AU + psoriatic arthritis |
| | 2/5 (40%) | AU + ulcerative colitis |
| | 6/7 (86%) | AU + Crohn’s disease |
|
|
Paiva et al. 2000 [20] | | 5/16 (31%) | Uveitis + psoriatic arthritis (PsA) |
| | 5/8 (62.5%) | Uveitis + PsA, and peripheral arthritis |
| | 0/8 (0%) | Uveitis + PsA, peripheral and/or axial arthritis |
| 89‡ | 29/89 (33%) | Uveitis + spondyloarthropathy |
|
|
Queiro et al. 2002 [21] | 13 | N.A.** | Uveitis + psoriatic arthritis |
|
|
Monnet et al. 2004 [13] | 175 | 76/175 (43%) | HLA-B27-associated AU |
| | 22/39 (56%) | AU without spondyloarthropathy† |
| | 54/136 (40%) | AU with spondyloarthropathy† |
| | 42/98 (43%) | AU + ankylosing spondylitis or presumed AS |
| | 8/21 (38%) | AU + undifferentiated spondyloarthropathy |
| | 0/2 (0%) | AU + psoriatic arthritis |
| | 2/6 (33%) | AU + reactive arthritis |
| | 1/5 (20%) | AU + spondyloarthropathy and Behçet’s disease |
| | 1/4 (25%) | AU + inflammatory bowel disease |
|
|
Braakenburg et al. 2008 [14] | 177 | 81/177 (46%) | HLA-B27-associated AU |
| | 15/39 (38%) | AU + HLA-B27-associated systemic disease |
| | 10/30 (33%) | AU + ankylosing spondylitis |
|
|
Chung et al. 2009 [15] | 504 | 169/504 (33.5%) | HLA-B27-associated AU |
| | 47/117 (40%) | AU without spondyloarthropathy |
| | 46/214 (21.5%) | AU + ankylosing spondylitis |
| | 69/150 (46%) | AU + undifferentiated spondyloarthropathy |
| | 4/10 (40%) | AU + psoriatic arthritis |
| | 3/11 (27%) | AU + reactive arthritis |
| | 0/2 (0%) | AU + inflammatory bowel disease |
|
|
Loh and Acharya 2010 [17] | 99 | 43/99 (43%) | HLA-B27-associated AU |
| | 18/44 (41%) | AU + HLA-B27-associated systemic disease |
|
|
Agnani et al. 2010 [16] | 207 | 91/207 (44%) | AU + HLA-B27 or axial spondyloarthritis |
| | 55/126 (44%) | AU + axial spondyloarthritis |
|
|
Zheng et al. 2012 [22] | 240 | 71/240 (30%) | HLA-B27-associated AU (6 were HLA-B27 negative) |
| | 19/108 (18%) | AU + ankylosing spondylitis |
| | 9/16 (56%) | AU + undifferentiated spondyloarthropathy |
|
